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Background: In addition to their effects on bone health, high doses of cholecalciferol may have beneficial non-classic
effects including the reduction of incidence of type 2 diabetes mellitus, cardiovascular disease, and cancer. These
pleiotropic effects have been documented in observational and experimental studies or in small intervention trials.
Vitamin D insufficiency is a frequent finding in renal transplant recipients (RTRs), and this population is at risk of
the previously cited complications.
Methods/design: The VITALE study is a prospective, multicentre, double-blind, randomized, controlled trial with
two parallel groups that will include a total of 640 RTRs. RTRs with vitamin D insufficiency, defined as circulating
25-hydroxyvitamin D levels of less than 30 ng/ml (or 75 nmol/l), will be randomized between 12 and 48 months
after transplantation to blinded groups to receive vitamin D3 (cholecalciferol) either at high or low dose (respectively,
100,000 UI or 12,000 UI every 2 weeks for 2 months then monthly for 22 months) with a follow-up of 2 years. The
primary objective of the study is to evaluate the benefit/risk ratio of high-dose versus low-dose cholecalciferol on
a composite endpoint consisting of de novo diabetes mellitus; major cardiovascular events; de novo cancer; and
patient death. Secondary endpoints will include blood pressure (BP) control; echocardiography findings; the incidences
of infection and acute rejection episodes; renal allograft function using estimated glomerular filtration rate; proteinuria;
graft survival; bone mineral density; the incidence of fractures; and biological relevant parameters of mineral metabolism.
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Discussion: We previously reported that the intensive cholecalciferol treatment (100 000 IU every 2 weeks for 2 months)
was safe in RTR. Using a pharmacokinetic approach, we showed that cholecalciferol 100,000 IU monthly should maintain
serum 25-hydroxyvitamin D at above 30 ng/ml but below 80 ng/ml after renal transplantation. Taken together,
these results are reassuring regarding the safety of the cholecalciferol doses that will be used in the VITALE study.
Analysis of data collected during the VITALE study will demonstrate whether high or low-dose cholecalciferol is
beneficial in RTRs with vitamin D insufficiency.
Trial registration: ClinicalTrials.gov Identifier: NCT01431430.
Keywords: Interventional trial, Vitamin D, Renal transplantation, Cancer, Cardiovascular events, Diabetes mellitusBackground
Vitamin D and vitamin D insufficiency in renal transplant
recipients
Traditionally, vitamin D has been associated with bone
health; its deficiency leads to rickets in children and osteo-
malacia in adults, and increases the risk of osteoporosis.
More recently, vitamin D sufficiency has been associated
with a reduced risk of many chronic diseases including
type 2 diabetes mellitus (T2DM), cardiovascular diseases,
cancers, and infectious diseases. All these diseases are
more likely to occur in renal transplant recipients (RTR)
than in the general population. Currently, the active form
of vitamin D is currently used after kidney transplantation
for the prevention of post-transplant bone loss [1] and the
treatment of normocalcemic persistent secondary hyper-
parathyroidism [2-4]. Treatment with active vitamin D
or its analogues will not compensate for inadequate 25-
hydroxyvitamin D (25OHD), however. 25OHD is a sub-
strate for 1α-hydroxylase (CYP27B1) in the kidney, and
also in several extrarenal tissues, and these extrarenal tis-
sues are dependent on adequate levels of 25OHD to ensure
adequate local calcitriol production. Although there is no
current consensus, vitamin D insufficiency is usually de-
fined as 25OHD levels lower than 30 ng/ml (or 75 nmol/l)
[5], because this limit is associated with a decrease in active
intestinal calcium absorption [6] and with an increase in
secretion of serum parathormone (PTH), which is involved
in maintenance of normal serum calcium levels [5]. Fur-
thermore, in interventional studies showing positive ef-
fects of vitamin D supplementation, the 25OHD levels
reached in the treated groups were generally higher than
30 ng/ml [7].
The vitamin D insufficiency is present in more than 85%
of adult RTRs [8]. Causes include: 1) insufficient vitamin D
supplementation before and after transplantation; 2) in-
creased 25OHD catabolism induced by immunosuppres-
sive drugs [9] and by post-transplant persistent fibroblast
growth factor-23 hypersecretion [10]; and 3) the reduced
sun exposure recommended to RTRs to prevent skin
cancers [11]. As a result, RTRs are now systematically
advised to protect themselves from exposure to solar
or artificial ultraviolet (UV) radiation. This representsa serious dilemma, as 80% to 90% of the human body’s re-
quirements for vitamin D result from photosynthesis of
the vitamin from 7-dehydrocholesterol in the skin by the
action of UVB radiation. Therefore, careful monitoring of
vitamin D status and oral supplementation to ensure that
vitamin D insufficiency does not occur is of great import-
ance for RTR.
Supplementation of vitamin D after renal transplantation
Despite the high prevalence of vitamin D insufficiency in
RTR, there is no general consensus regarding vitamin D
supplementation after transplantation. In one study, [12],
it was shown that high doses of vitamin D3 (100,000 IU
cholecalciferol every other week for 2 months, equivalent
to 6,600 IU/day) were able to correct 25OHD insufficiency
in RTRs without significant side effects, and this regimen
was also associated with a significant decrease in serum
PTH concentration. However, this study also indicated
that the dose of cholecalciferol used during the mainten-
ance phase (100,000 IU every other month from months 6
to 12 post-transplantation) was insufficient to maintain
serum 25OHD concentration above 30 ng/ml in half of
patients [12]. Another study showed that 25,000 IU of
cholecalciferol once a month failed to correct vitamin
D insufficiency in RTRs, suggesting that a higher dose
of cholecalciferol is necessary to maintain adequate
25OHD levels after transplantation [13]. The optimal
dosage scheme was simulated from the data of a previous
study [12] using a population pharmacokinetic approach.
In order to maintain 25OHD concentrations between 30
and 80 ng/ml during the first year after renal transplant-
ation, it was estimated that cholecalciferol dosing should
be 100,000 IU once a month once correction of vitamin D
insufficiency has been achieved [14].
Anticancer properties of vitamin D
RTRs exhibit an increased incidence of cancers, especially
of non-melanoma skin cancers and non-Hodgkin lymph-
oma. Data from the US Renal Data System indicate that at
3 years after renal transplantation, there is a 7.5% cumula-
tive incidence of non-skin cancers and a 7.4% cumulative
incidence of skin cancers in RTRs [15]. The role of vitamin
Courbebaisse et al. Trials 2014, 15:430 Page 3 of 14
http://www.trialsjournal.com/content/15/1/430D status in cancer risk has received strong experimental
support from the consistent demonstration that activation
of the vitamin D receptor (VDR) by locally produced
calcitriol induces differentiation [16] and apoptosis [17],
and inhibits cell proliferation [18] and angiogenesis [19].
Moreover, vitamin D and its metabolites stimulate mutual
adherence of cells and intercellular communication through
gap junctions, thereby decreasing metastatic potential
and strengthening the inhibition of proliferation that re-
sults from tight intercellular physical contacts [20]. Many
prospective case–control studies have shown that adults
in the highest quantile of 25OHD levels have a decreased
risk of colon [21] and breast [22] cancers compared with
those in the lowest quantile. Furthermore, the risk of non-
Hodgkin lymphoma is reduced by 30% to 40% in adults
with high vitamin D intakes [23] or high levels of sun ex-
posure [24]. Finally, retrospective studies suggest an asso-
ciation between low serum 25OHD level and death from
cancer [25-27]. It must be mentioned that in a few obser-
vational studies a U-shaped (or rather an inverse J-shaped)
curve between 25OHD serum levels and the risk of
prostate [28], or pancreatic cancer [29] has been found
(increased risk for both low and high serum 25OHD levels).
However, it is a consensus that causality cannot be estab-
lished from observational studies, so that randomized
controlled trials (RCTs) evaluating the effect of vitamin
D supplementation on the risk of cancer (versus placebo)
are needed to firmly determine whether low and/or high
vitamin D status increases the risk of cancer.
Such interventional studies of vitamin D supplementa-
tion in humans have yielded controversial data, however.
In the Women’s Health Initiative (WHI) study, 36,282
women were randomized to receive either a placebo or
1000 mg calcium and 400 IU vitamin D3 daily. Although a
strong negative relationship between baseline 25OHD
levels and the incidence of colorectal cancer was found,
no reduction in the incidence of cancers was observed
in the treated group compared with the placebo group
[30]. Of note, adherence to treatment was poor, and chole-
calciferol dosage was considered to be too low by many ex-
perts in that study. Furthermore, women included in the
WHI trial were allowed to continue to take the calcium/
vitamin D supplementation that they were taking prior to
enrolling in the study, so that some women in the placebo
group received more vitamin D during the study than
some women included in the calcium+ vitamin D group.
When the analysis was restricted to those women who were
not taking calcium or vitamin D supplementation before
the study, a significant reduction in the risk of total and
invasive breast cancer, as well as in the risk of total can-
cer, was found [31]. A 4-year, double-blind, randomized,
placebo-controlled trial comprising 1,180 postmenopausal
women showed a significant decreased risk of cancers in
the group receiving calcium (1,500 mg/day) plus vitaminD3 (1,100 IU vitamin D3/day) supplementation [32],
whereas another 3-year, double-blind, randomized, placebo-
controlled trial comprising 5,292 patients aged over 70 years
showed no reduction in cancer incidence with vitamin D3
800 IU per day [33]. To our knowledge, no interven-
tional study has reported that vitamin D supplementa-
tion increases the risk of any cancer, although it must be
emphasized that the doses used were generally too low
and the duration of the studies too short to conclude this
definitely.
The potential protective role of vitamin D against cancer
risk was also assessed in RTRs [34]. In a cohort of 363
RTRs followed up during 3 to 5 years after transplantation,
a higher incidence of post-transplant cancers was observed
in patients with pre-transplant 25OHD concentrations
less than 10 ng/ml (13.7% vs. 3.7% for those with 25OHD
levels >30 ng/ml, P =0.007). Another study reported no as-
sociation between cancer incidence and vitamin D status
over a 10-year follow-up period after renal transplantation
[35], although a single repletion study showed a decrease
in cancer risk in RTRs treated with active vitamin D [36].
Whether these results can be explained by risk segrega-
tion with cancer type, particularly viral-related cancers,
remains to be established.
The relationship between sun exposure and non-me-
lanoma skin cancer also remains to be elucidated. Even
though the role of sun exposure has been demonstrated,
it should be note that VDR knockout (KO) mice develop
UVB-induced skin cancers more rapidly and more fre-
quently than wild-type mice, suggesting a potential pro-
tective role for 25OHD against non-melanoma skin cancers
[37]. In RTR, regular application of sun protection factor
(SPF) 50 sunscreen is associated with fewer skin lesions
but also with lower 25OHD levels [38]. The association
of higher levels of 25OHD with an increased risk of skin
cancer can be explained by greater UV exposure [39].
These data highlight the difficulties of drawing conclusions
using only epidemiological and not interventional studies.
Anti-diabetic properties of vitamin D
According to the diagnostic criteria and post-transplan-
tation delay, de novo T2DM occurs in 10% to 30% of
RTR, mainly due to corticosteroid and tacrolimus treat-
ment [40]. The potential effects of vitamin D on insulin
secretion and insulin resistance are supported by experi-
mental data [41]. First, VDR [42] and CYP27B1 [43] are
expressed in pancreatic β cells, and vitamin D responsive
elements (VDRE) have been identified in the promoter
of the human gene encoding insulin [44]. Second, in vitro
studies have shown that calcitriol stimulates transcription
of the insulin gene, expression of insulin receptor, and glu-
cose transport [41]. Third, VDR knockout (KO) mice have
abnormal insulin secretion [45], and vitamin D3 supple-
mentation increases glucose tolerance and insulin secretion
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concentrations are inversely correlated with T2DM preva-
lence [41,47-49]. Vitamin D insufficiency is also associated
with increased glycated hemoglobin (HbA1c) levels [50]
and resistance to insulin [47]. The influence of vitamin
D on the resistance to insulin may be partly mediated by
calcitriol, through control of the gene encoding adiponec-
tin [51]. In a very recent paper, it was reported that vitamin
D and calcium supplementation decreased serum interleu-
kin (IL)-6 and tumour necrosis factor-α concentrations in
patients with T2DM, and might thus improve systemic in-
flammation in this disease [52]. A recent meta-analysis of
RCTs showed that active or native vitamin D supplementa-
tion improved fasting glycaemia and insulin resistance
in patients with glucose intolerance, but had no effect on
HbA1c levels [53]. However, another recent meta-analysis
found no effects of vitamin D supplementation on glu-
cose homeostasis or diabetes prevention, although a trend
(P =0.06) towards reduction in fasting blood glucose in
patients with pre-diabetes, and a significant reduction
in homeostatic model assessment of insulin resistance
(HOMA-IR) after exclusion of the studies that admin-
istered a single large dose of vitamin D were reported
[54]. These authors indicated also that definitive conclu-
sions may be limited because of heterogeneity in the stud-
ies, variable risk of bias, and the short-term follow-up
duration of the available evidence to date, again empha-
sizing, as mentioned above for the potential effects of
vitamin D on cancers, the need for large, well-conducted
RCTs. To date, no study has reported the potential effect
of active or native vitamin D on de novo T2DM after
transplantation.
Effects of vitamin D on the cardiovascular system
In comparison with the general population, RTRs have
an increased cardiovascular risk secondary to both trad-
itional and non-traditional risk factors (50-fold higher in
RTRs) [55]. Observational and experimental data argue
in favour of a potential protective role of vitamin D against
cardiovascular disease. Cross-sectional studies have indi-
cated that vitamin D deficiency is associated with arterio-
sclerosis and endothelial dysfunction in patients with
end-stage renal disease [56]. Several prospective case–
control studies have reported a strong association between
low circulating levels of 25OHD and an increased risk of
major cardiovascular events such as myocardial infarction,
stroke, congestive heart failure [57,58], and cardiovascular
disease death [59-62]. These associations remained signifi-
cant after adjustment for other risk factors for cardiovas-
cular disease.
Possible explanations for these findings involve both
direct and indirect effects of vitamin D on cardiovas-
cular function. Direct effects are supported by the fact
that cardiomyocytes, vascular smooth muscle cells, andendothelial cells express both VDR and the CYP27B1
enzyme [63]. Furthermore, genes upregulated during myo-
cardial hypertrophy (such as atrial natriuretic peptide) pos-
sess VDREs, and are suppressed by calcitriol in animal and
cell models [64]. Similarly, in cultured cells, calcitriol
inhibits cardiomyocyte proliferation [65], and stimulates
vascular smooth muscle cell proliferation and vascular
endothelial growth factor expression by these cells [66].
Calcitriol also modulates contractile performances of iso-
lated rat and mouse cardiomyocytes [67,68].
Potential indirect consequences of vitamin D deficiency
may underlie its role as a risk factor for cardiovascular dys-
function. VDR but also CYP27B1 KO mice have high BP
levels and cardiac hypertrophy due to increased activation
of the renin-angiotensin system (RAS) [69], and calcitriol
treatment inhibits renin activation and decreases BP and
cardiac hypertrophy in CYP27B1 KO mice [70]. Calcitriol
also reduces the expression of the metalloproteinases
(MMP) MMP2 and MMP9 [71]; expression of these two
MMPs appears to promote vascular calcification [72]. In a
recently published mendelian randomization study per-
formed in 142,255 individuals, increase in an allele score
based on variants of genes that affect 25OHD synthesis or
substrate availability, and used as a proxy for 25OHD
concentration, was found to be significantly associated
with reduced odds of hypertension [73]. Even though
no controlled interventional trials with clinical cardio-
vascular endpoints have been performed, numerous stud-
ies have shown either no or positive effects of vitamin D
supplementation on intermediary parameters potentially
related to cardiovascular health such as BP, endothelial or
left ventricular function, and lipid profile [74]. Interest-
ingly, a meta-analysis of 11 randomized trials either with
active or native vitamin D confirmed this reduction in
systolic BP in patients with hypertension, and suggested
that native vitamin D produced a greater fall in systolic BP
than activated compounds [75]. In that meta-analysis, posi-
tive effects of vitamin D supplementation on BP were mod-
est and limited to patients with hypertension. Another
potential cause explaining negative results of vitamin D
trials on BP was suggested by the results of a recent 20-
week study performed in 130 patients with moderate
hypertension who received either 3,000 IU vitamin D3
daily or a placebo [76]. The primary objective, ambulatory
BP (24 h BP), was not significantly modified in the vitamin
D group compared with placebo in the intent-to-treat
(ITT) analysis, although central BP, a secondary endpoint,
was significantly reduced. However, in a post hoc analysis
limited to the 92 patients with a baseline 25OHD level of
less than 32 ng/ml, 24 h BP was modestly but significantly
reduced. This may partly explain why ITT meta-analyses
of studies on the effect of vitamin D on BP that include
both patients with normal and patient with high BP, as
well as patients with or without vitamin D deficiency, may
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patients with hypertension and vitamin D insufficiency.
Interventional studies targeted to the effect of vitamin D
supplementation on major cardiovascular events and using
death as a primary endpoint do not yet exist. In a second-
ary analysis of the RECORD trial on four pre-specified
outcomes, vitamin D supplementation was found to protect
against cardiac failure (HR =0.75; CI 0.58 to 0.97), but not
against myocardial infarction or stroke [77]. However,
several recently published meta-analyses of interventional
studies (whose primary endpoint was not cardiovascular
events) found no (positive or negative) effect of vitamin D
supplementation on major cardiovascular events [77-79],
although a slight, but significant decrease in all-cause mor-
tality was reported [79-81]. To date, the few, weakly pow-
ered, observational studies performed in RTRs have found
no robust association between serum 25OHD levels and
cardiovascular risk factors [35,82,83]. The apparent dis-
crepancy between the strong association of vitamin D
deficiency with major cardiovascular events and the lack
of strong evidence of a reduction in cardiovascular risk
with vitamin D supplementation may be due to reverse
causation, which frequently affects observational studies
(low vitamin D being the consequence rather than the
cause of the disease under study).
However, because vitamin D intoxication in humans may
lead to vascular calcifications, the benefit/risk ratio of
supraphysiologic dosages of vitamin D should be evalu-
ated, especially in RTRs having an increased cardiovas-
cular risk. Indeed, a biphasic effect of vitamin D on the
risk of vascular calcifications is likely [84]. It has been
recently reported from observational studies that the risk
of all-cause mortality [85] and the risk of major cardiovas-
cular events [86,87] increased if serum 25OHD levels were
below 20 ng/ml but also if levels were above 40 ng/ml. Al-
though no causality can be concluded from observational
studies, these results should incline the medical commu-
nity to be cautious with regard to high-dose vitamin D
supplementation and cardiovascular health.
Methods
Objectives
The VITALE study is designed to evaluate whether high
doses of cholecalciferol in RTRs with vitamin D insuffi-
ciency has beneficial effects upon the late post-transplant
outcome compared with low-dose supplementation. As a
primary outcome, we will evaluate the impact of cholecal-
ciferol on a composite endpoint including de novo DM
(fasting glycaemia >7 mmol/l or glycaemia >11 mmol/l),
major cardiovascular events (acute coronary heart disease,
acute heart failure, lower-extremity arterial disease, cere-
brovascular disease), de novo cancer, and patient death.
Secondary objectives will compare the effects of high-dose
versus low-dose cholecalciferol on BP and on BP control(number and dosage of antihypertensive drugs), echocar-
diography findings, infections (including cytomegalovirus,
Pneumocystis, nocardial infection, cryptococcal infection,
aspergillosis), acute rejection episodes, renal allograft func-
tion including Modification of the Diet in Renal Disease
(MDRD)-v4 estimated glomerular filtration rate (eGFR)
[88], proteinuria and graft survival, and mineral metabol-
ism biologically (serum calcium, phosphate, 25OHD and
PTH) and clinically (graft nephrolithiasis, bone mineral
density, measured body weight, and incidence of fractures)
relevant parameters.
We have noted that, according to the published literature,
some vitamin D experts especially involved in the cardio-
vascular field consider that optimal 25OHD concentration
for cardiovascular health probably lies within a narrow
range of 30 to 40 ng/ml [89,90]. We took this advice into
account, and one of the main objectives of our VITALE
trial is thus to evaluate whether our treatment scheme,
which probably will increase the 25OHD concentration
above 40 ng/ml in a significant percentage of patients, is
safe, especially in terms of cardiovascular health.
Study population and sample size
The study sample will consist of 640 RTRs found to be
lacking sufficient vitamin D (25OHD <30 ng/ml) 12 to
48 months post-transplantation with 320 subjects in each
study group. Inclusion and exclusion criteria are detailed in
the Appendix. The sample size calculation was performed
according to the following assumptions: The principal cri-
teria will be the occurrence of one of the events of the
composite endpoint including de novo DM, major cardio-
vascular events, de novo cancer, and patient death. Over a
2-year follow-up period, we estimate, according to previous
reports in the literature, that the incidence of a first event
of the composite endpoint will be around 22% in our
population (6% for de novo T2DM [91,92], 6% for major
cardiovascular events [93-95], 7% for de novo cancers
[15,96], and 3% for patient death). This 22% global esti-
mated incidence does not take into account the fact that
some patients may experience several events of the com-
posite endpoint during the follow-up period. According to
the results of the numerous observational studies showing
an inverse association between 25OHD concentrations and
various clinical events and to the results of the few
interventional trials showing effects of high-dose vitamin
D supplementation on these events (detailed above),we es-
timate that the overall decrease in the incidence risk of a
first event of the composite endpoint will be around 40%
in the high-dose group compared with the low-dose group
(33% decrease for de novo DM, 40% decrease for major
cardiovascular events and 50% decrease for de novo can-
cer). Thus, to demonstrate the reduction in the incidence
of a first event of the composite endpoint from 22% in the
low-dose group to 13% in the high-dose group, with a 90%
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will be required. Taking into account that 10% of patients
will not be evaluable, a total of 640 RTRs will be required.
The inclusion of a total of 480 RTRs would allow us to test
the same hypothesis with a power of 80%.
Study design and setting
The VITALE study is a prospective, multicentre, double-
blind, randomized trial with two parallel groups. Patient
recruitment, kidney transplants, postoperative care, and
follow-up are currently conducted in 30 transplantation
departments in France, and there are about 2,700 kidney
transplantations performed each year in France. In the ab-
sence of vitamin D supplementation, approximately 80%
of RTRs are expected to have insufficient vitamin D. Of
these patients, 20% to 30% are expected to fulfil the inclu-
sion criteria and to agree to participate in the study. Con-
sequently, the recruitment phase will last approximately
2 years, with a follow-up period of 2 years for each subject.
The flowchart of the VITALE study is shown in Figure 1.
Randomization and blinding
If all inclusion and none of the exclusion criteria are met
and informed consent has been obtained, each RTR will
be included in the study and allocated a randomization
number used for assignment to one of the two treatment
arms. The randomization list will be computer-generated-RTR, 12-48 months post-transplant 
-25OHD< 30 ng/mL
RANDOMIZATION
CLC : 100 000 IU
= intensive trea
(Eq 6600 IU dai
M0
CLC : 12000 IU
(Eq 800 IU da





Figure 1 Flowchart of the VITALE study. RTR with 25OHD insufficiency (
transplantation in 30 transplantation departments in France, and randomiz
every other week, equivalent to 6,600 IU daily for 2 months, then 100,000 I
cholecalciferol treatment (12,000 IU every other week, equivalent to 800 IU
for 22 months, which is the French recommended dietary intake). Duration
a single-dose vial of 100,000 or 12,000 IU have exactly the same appearanc
low-dose group) over a period of approximately 2 years. Statistical analysisand created using nQuery Advisor software (v6.01). The
randomization will be stratified by centres, and blocks of
four will be used in order to facilitate treatment distribu-
tion by the central pharmacy. The size of the blocks will
be unknown to the investigators. The two treatment regi-
mens will be randomly allocated in a 1:1 ratio. The attri-
bution arm will be given centrally by Cleanweb® software
after the validation of inclusion criteria, and this software
also allows entering trial data for each patient. Partici-
pants, investigators, and outcome assessors will be blinded
to the allocated treatment. Blinding will be ensured by the
use of investigational products that are identical in pack-
aging, labelling, appearance, smell, and taste. Unblinding
will occur only in cases of emergency or at the conclusion
of the study. In most cases, discontinuation of the treat-
ment should be sufficient without the need for unblinding.
Access to the randomization list will be restricted to the
pharmacist involved in the study and a research assistant.
Study intervention
At 12 to 48 months after renal transplantation, RTRs found
to have 25OHD levels below 30 ng/ml and who fulfil all of
the inclusion and none of the exclusion criteria will be
randomized to receive either high-dose y (100,000 UI every
2 weeks for 2 months, then monthly for 22 months) or
low-dose (12,000 UI every 2 weeks for 2 months, then
monthly for 22 months) oral cholecalciferol therapy. With every other week
tment
ly)
CLC : 100 000 IU monthly
= maintenance treatment
(Eq 3300 IU daily)
M2 M24
 every other week
ily)
CLC: 12000 IU monthly
(Eq 400 IU daily)
Follow-up= 2 years
Stascal analysis
25OHD <30 ng/ml) will be included 12 to 48 months after renal
ed to receive either high-dose cholecalciferol treatment (100,000 IU
U monthly, equivalent to 3,300 IU daily for 22 months) or low-dose
daily for 2 months, then 12,000 IU monthly, equivalent to 400 IU daily
of patient follow-up will be 2 years. VITALE is a double-blind study as
e. We aim to include 320 RTR sin each group (high-dose group and
will be performed at the end of the study.
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either cholecalciferol 100,000 IU or 12,000 IU plus butyl-
hydroxytoluene 0.2 mg, saccharin 1.2 mg, sorbic acid
4.00 mg, lemon essential oil 6.0 mg, with glycosylated
polyoxyethylenated glycerides making the quantity up
to 2 ml. High-dose and low-dose vials will be produced
by Crinex (Montrouge, France). It will be recommended
that cholecalciferol be ingested concomitantly with a fatty
meal to improve intestinal absorption of vitamin D3 [97].
The intensive phase of the high-dose arm was previously
demonstrated to correct 25OHD insufficiency in RTRs
[12], and the maintenance phase was demonstrated in a
theoretical scheme to maintain 25OHD above 30 ng/ml
after kidney transplantation [14]. The 12,000 IU cholecal-
ciferol monthly dose during the 22 month-maintenance
phase, equivalent to 400 IU daily, was chosen because it is
in agreement with the French recommended dietary in-
take [98], and this dose has been proven to avoid severe
vitamin D deficiency and osteomalacia [99]. To evaluate
adherence to treatment, patients will be asked to return
the treatment boxes containing the empty ampoules at
each follow-up visit.
The two side effects caused by vitamin D3 that may occur
are increase in serum calcium levels or in urinary calcium
excretion. At serum calcium levels >2.85 mmol/l, serum
phosphate levels >1.8 mmol/l or in cases of major increase
in urinary calcium excretion (increase in fasting baseline
urinary calcium/creatinine ratio ≥0.4 mmol/mmol in the
absence of furosemide introduction), the aforementioned
monthly vitamin D3 administration will be discontinued.
If the biological abnormalities cited above persist after
vitamin D3 re-introduction, cholecalciferol treatment will
be halted. Cholecalciferol treatment will be immediately
discontinued in cases of proven graft nephrolithiasis (except
for uric acid calculi, whose composition has been proven
by calculi analysis) or nephrocalcinosis, symptomatic
hypercalcemia, or pregnancy occurrence. VITALE is an
ITT study. Consequently, in cases of cholecalciferol dis-
continuation, patient follow-up will be maintained accord-
ing to the study guidelines until the end of the 24 month
follow-up period.
Concomitant medication
Most RTRs are treated with an immunosuppressive ther-
apy consisting of mycophenolate mofetil or sodicum myco-
phenolate, tacrolimus, or ciclosporin, with (in most cases)
or without prednisone. Steroid boli, monoclonal antibodies,
and polyclonal antibodies are administered to treat acute
rejection episodes. Medications will be allowed during the
study, with the exception of active or native vitamin D2,
active or native D3, and multivitamin complexes likely to
contain vitamin D. Drugs with anti-secretory and gastric-
dressing properties will be allowed, but will have to be
ingested at least 4 hours after cholecalciferol treatment.Study procedure
Inclusion visit
At 12 to 48 months after kidney transplantation, each RTR
found to have 25OHD levels below 30 ng/ml during a
routine visit will be given information about the VITALE
study, its purpose, putative benefits, and possible risks, and
will be invited to participate in the trial. All patients will be
informed that the participation in that study is voluntary,
and that they may refuse to participate or withdraw from
the trial at any time without giving reasons and without
loss of benefits. RTRs who do not agree to participate in
the study will receive standard care. If the RTR agrees,
they will sign a written informed consent form, and demo-
graphic, clinical, and biological baseline data will be col-
lected. In addition, daily calcium intake will be evaluated
by means of a questionnaire.
Randomization
During the week following the inclusion visit, RTRs who
agree to participate in the study will be randomized to
receive either oral high-dose vitamin D3 therapy or oral
low-dose vitamin D3 therapy. The day of the randomization
defines the first day of the study.
Patient follow-up
Five visits will be performed after randomization (Table 1).
Vitamin D measurements after randomization will be cen-
tralized and performed at the end of the study. Given
the absence of standardization and a reference method of
vitamin D measurement when we submitted the VITALE
trial to funders (early 2011), we planned to use the most
referenced method (radioimmunoassay; Diasorin, Stillwater,
MN, USA) [100]. Since then, a reference method has been
accepted [101] and is now being used in an international
program, the Vitamin D Standardization Program (VDSP),
to harmonize vitamin D results [102]. We thus will use the
assay (either immunoassay or commercial LC-MS-MS
assay) that at the end of the VITALE study will provide re-
sults that are closest to the reference method [103]. This
will allow us to determine with the best possible precision
the optimal threshold of 25OHD level to prevent the oc-
currence of the clinical events constituting the principal
criteria. In order to assess compliance, patients will be
asked to return their empty vials at each follow-up visit.
Statistical analysis
Descriptive analysis
Patients will be described according to their initial treat-
ment group attributed after the randomization. A flowchart
of enrolled and analysed patients will be provided. Demo-
graphic, clinical, and biological characteristics recorded
at time of randomization will be described. Descriptive
analyses will use numbers (percentages) for qualitative
variables, mean ± standard deviation or median (first to
Table 1 Study procedures
Date Patients selection Inclusion visit M1 M2 M3 M6 M12 M18 M24




Written informed consent/checking of
the inclusion and exclusion criteria
X
Medical history entry X
Clinical examination, blood pressure,
body weight and height
X X X X X X
Current treatment X X X X X X
Notification of events constituting the primary
composite criteria and the secondary criteria
X X X X X
Checking of treatment compliance X X X X X
Notification of tolerance and side effects2 X X X X X
β-human chorionic gonadotropin if relevant X
25OHD < 30 ng/ml X X1 X1 X1
Serum calcium2 <2.7 mmol/l X X X X X X
Serum phosphate2 <1.5 mmol/l X X X X X X
Fasting urinary calcium2 X X X X X X
Fasting urinary creatinine2 X X X X X X
Serum creatinine <250 μmol/l X X X X X X
MDRD estimated glomerular filtration rate X X X X X X
Urinary protein/creatinine ratio X X X
Urinary microalbumin/creatinine ratio X X X
Fasting glycaemia < 7 mmol/l X X X X X X
HbA1C X X X
Liver function tests X X
Lipid profile X X X
Complete blood count X X X
Serum parathyroid hormone X X X
Bone mineral density X X
Echocardiography2 X X X
DNA collection3 X
Serum collection3 X X X X
Table legend: M1 (M2, 3…): month one (two, three…) after randomization; MDRD: Modification of the Diet in Renal Disease; R: randomization; T0: time zero
corresponding to the randomization of the patient.
1R: randomization represents the time 0 (T0). Intensive phase: cholecalciferol 100,000 IU or 12,000 IU every two weeks for 2 months. Maintenance phase:
cholecalciferol 100,000 IU or 12,000 IU monthly for 22 months.
2Safety data. Echocardiography results will have to notify valvular calcifications.
3Samples for which the dosage (25OHD) and/or conservation will be centralized.
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and Kaplan-Meir curves or cumulative incidences in
the presence of competing risks for time to event. No
statistical test will be formally performed to compare
the initial characteristics of randomized groups.
Statistical analysis
The ITT analysis will involve data on all patients in each
dose group. All patients who are lost to follow-up for any
reason will be treated as failures at the time of last contact
or at the time of an event that results in discontinuation,whichever occurs first. The per-protocol set will exclude
from the full analysis the set non-compliant patients, pa-
tients who received less than 50% of the treatment, and
patients who received concomitant administration of an
excluded treatment.
All events occurring during the 2 years of follow-up will
be recorded. The principal criteria (occurrence of the first
event constituting the composite endpoint) will be com-
pared between the two groups using the Cox model that
takes into account the stratification by the centre. Second-
ary criteria will be compared using tests corresponding to
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qualitative variables, parametric or non-parametric vari-
ance analysis for quantitative variables, and log-rank or
Gray’s test for time to event. The secondary parameters
that will be analysed are the following: the incidence of
each of the events constituting the composite primary
endpoint; BP measurement, and number, drug classes and
doses of antihypertensive drugs necessary to reach normal
BP; preventive coronary revascularisation; evolution of the
left ventricular ejection fractions and of the left ventricular
wall thickness assessed by transthoracic echocardiography;
vitamin D insufficiency correction; evolution of the fasting
urinary calcium/creatinine ratio and of serum calcium,
phosphate, and PTH concentrations; bone fracture inci-
dence; changes in body height; changes in bone mineral
density at the lumbar spine and femoral neck; incidence
of infectious episodes and type of infection; incidence of
treated acute rejection episodes; evolution of MDRD
eGFR, of urinary protein/creatinine ratio, and of urinary
microalbuminuria/creatinine ratio; graft survival; evolution
of HbA1C in the absence of DM; evolution of HbA1C and
of anti-diabetic treatments in cases of de novo DM; or
incidence of cholecalciferol-related side effects (hypercal-
caemia, calcic nephrolithiasis and other spontaneously re-
ported side effects). Adjustment for multiple testing will
be performed using the Hochberg procedure for the com-
ponents of the primary criteria. We will also describe in
detail each adverse event (AE) that occurs during the
study, and we will report the overall rate of occurrence
of AE, the rate of withdrawal from the study due to an
AE, the overall rate of patients with at least one clinic-
ally significant laboratory abnormality, the rate of AEs
attributable to treatment (possible or probable relation-
ship), and the rate of serious AEs. The percentage of pa-
tients with each of the AEs associated with cholecalciferol
and the intensity of these AEs will be specified.
Some additional post hoc subgroup analyses will also be
performed (according to, for example, baseline 25OHD
levels, achieved 25OHD levels, VDR and vitamin D bind-
ing protein polymorphisms, and corticosteroid treatment,
among others).
Approval of the ethics committee and the regulatory
authority
The proposed study will be conducted in accordance with
the Declaration of Helsinki and with French law, and will
subscribe to the principles outlined in the International
Conference on Harmonization on Good Clinical Practice,
2002. A favourable opinion was delivered by the Ethics
CommitteeCCP-IDF1 (Committee for the Protection of
Persons-Ile-de France 1) with the reference number 2011-
mars-12559. In France, every trial is approved by a sin-
gle ethics committee for each involved centre, accord-
ing to the legislation for the studies funded by a researchgrant from the French Ministry of Health, as is the
case for our study (VITALE = PHRC P100103). The local
ethics committee of each centre is not subsequently in-
volved. Furthermore, the study has been registered in a
public clinical trial database (ClinicalTrials.gov Identifier:
NCT01431430).Discussion
Risk analysis
Vitamin D intoxication does not occur if 25OHD concen-
tration remains at less than 150 ng/ml [104]. There is no
evidence that the margin of safety for vitamin D3 differs in
patients with renal disease compared with the rest of the
population [104]. Several studies have shown that daily
doses of vitamin D significantly higher than the recom-
mended dietary intake (more than 4,000 IU per day and
up to 10,000 IU per day) do not affect urinary calcium or
serum calcium levels [105-108]. There have also been stud-
ies of the effect of spaced high doses, which likewise re-
ported no indication of vitamin D toxicity [107,109]. Most
importantly, we have previously reported that the high-
dose intensive cholecalciferol treatment we intend to use
(100,000 IU every 2 weeks for 2 months) was safe in RTRs
[12]. Using a pharmacokinetic approach, we determined
that cholecalciferol 100,000 IU monthly should maintain
25OHD above 30 ng/ml but below 80 ng/ml [14]. Taken
together, these results suggest that the doses of cholecalcif-
erol to be used in the VITALE study will be safe. No other
AEs of vitamin D supplementation have been reported in
the published intervention studies. However, as several ob-
servational studies have reported an inverse J-shaped curve
between 25OHD serum levels and several hard endpoints
such as cardiovascular major events and some cancers, we
will be monitoring carefully for any signs of possible AEs.
For our study, we have chosen a composite criterion for
efficacy. The main advantages supporting this choice are
that it increases statistical efficiency because of a higher
event rate, which reduces sample size requirement. In
addition, it helps investigators avoid an arbitrary choice
between several important outcomes that refer to the same
disease process. Composite outcomes can be misleading
when treatment effects vary across components with very
different clinical importance. In our study, the rate of each
event except for death is of similar magnitude. Moreover,
we hypothesize that the rate reduction of each event com-
posing the endpoint will be between 30% and 50%, giving a
mean reduction of 40% overall. We also hypothesize that
the drug will not affect death, but death is being included
in the composite endpoint because it is a competing risk
with major cardiovascular events. In order to limit mislead-
ing interpretation, we will clearly present data for all com-
ponents and discuss the role of each in the total reduction
of the composite event rate.
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effects of vitamin D3 on extra-osseous criteria after renal
transplantation
Two other studies are also testing the effect of native
vitamin D on extra-osseous diseases after renal transplant-
ation [110]. The VITA-D study (Vitamin D3 Substitution
in Vitamin D Deficient Kidney Transplant Recipients;
ClinicalTrials.gov Identifier: NCT00752401) is also a
double-blind, randomized, placebo-controlled study of
RTRs deficient in vitamin D, focusing on the impact of
cholecalciferol substitution on graft function (MDRD
eGFR), incidence of acute rejection episodes, and post-
transplant infections within the first year after trans-
plantation. In total, 200 RTRs with 25OHD of less than
20 ng/ml at time of transplantation will be randomized
to receive either cholecalciferol (6,800 IU/day during one
year) or placebo [111]. The CANDLE-KIT study (Correct-
ing Anemia and Native Vitamin D Supplementation in
Kidney Transplant Recipients; ClinicalTrials.gov Identifier:
NCT01817699) is another open-label RCT with four arms:
1) no intervention: low haemoglobin (Hb) target (Hb
level: ≥9.5 and <10.5 g/dL) without cholecalciferol; 2) low
Hb target with cholecalciferol 1,000 IU/day; 3) high Hb tar-
get (Hb level: ≥12.5 and <13.5 g/dL) without cholecalciferol,
and 4) the experimental arm: high Hb target with cholecal-
ciferol 1,000 IU/day. This study will recruit 324 RTRs, who
are at least q year post-transplantation. The primary end-
point will be the change in allograft kidney function using
MDRD eGFR. Among he secondary endpoints are urinary
markers of kidney injury, the dose of methoxypolyethylene
glycol epoetin β required to maintain the target haemo-
globin level, BP, cardiac biomarkers, left ventricular mass
index, acute cellular rejection, bone-turnover markers,
intact PTH, bone mineral density, cardiovascular events,
all-cause death, and cancer development or recurrence.
Numerous criteria of these two studies are part of the pri-
mary composite endpoint or of the secondary endpoints
in the VITALE study.
Conclusion and perspectives
In addition to its classic effects on bone and mineral me-
tabolism, vitamin D displays a wide spectrum of potential
non-classic effects that are especially relevant for the care
of RTRs. These pleiotropic effects have been documented
in observational and experimental studies or small inter-
vention trials, which most often evaluated intermediate
parameters. The time has now come for large placebo-
controlled trials in RTRs, using larger dosages of vitamin
D than the current recommended intakes, and targeting
clinical endpoints. The VITALE study has been designed
to demonstrate that high doses of vitamin D can reduce
the risk of extra-osseous diseases without inducing AEs,
and also aims to determine the necessary levels of 25OHD
to achieve these effects. Furthermore, the RTR populationmay give interesting clues to the effects of vitamin D in the
general population, as cardiovascular, diabetes mellitus,
and cancer complications are much more frequent in






 RTRs who are between 12 and 48 months after
transplantation with stable renal function during the
past 3 months
 Vitamin D insufficiency, defined as a concentration
of 25OHD lower than 30 ng/ml
 Aged between 18 and 75 years old
 Capable of understanding the advantages and the
risks of the study
 Have social security health insurance
 Have provided written informed consent
Exclusion criteria
 Calcaemia >27 mmol/l
 Phosphataemia >15 mmol/l
 Serum creatinine >250 μmol/l
 Receiving treatment with an active form of vitamin
D,which cannot be interrupted
 Transplant of an organ other than the kidney
 Type 1 or type 2 DM
 Medical history of granulomatosis
 Primary hyperoxaluria
 Proven malabsorption of liposoluble vitamins
 Simultaneous participation in another therapeutic
clinical trial
 Drug addiction or a psychiatric disorder
 Pregnancy or breast-feeding
 Vitamin D hypersensitivity
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